Heston Blumenthal said he will reduce portion sizes and introduce smaller‑menu options at his flagship restaurant, The Fat Duck, to accommodate diners whose appetites have been suppressed by injectable weight‑loss drugs.
The three‑Michelin‑star chef said he and his team will "look at reducing portion sizes and give options of a much smaller menu," citing the growing number of customers taking medications such as Wegovy, Mounjaro and Ozempic. "With these weight‑loss drugs... people are eating less and the quantities of food will put them off — I want to do something about that," he told industry journal Restaurant.
Blumenthal, 59, who owns the three‑Michelin‑star Fat Duck in Bray and the one‑Michelin‑star Hinds Head gastropub, said the changes come as the restaurant marks its 30th anniversary. He has previously described the situation as a "paradox" for a restaurateur, because he has been taking the drug Wegovy himself to offset weight gain associated with medication for bipolar disorder; he disclosed a diagnosis of type 1 bipolar in 2023 and told Times Radio last month that he had begun using Wegovy.
The chef has also urged broader industry and government attention to what he called a potential threat to the pub and restaurant trade. At the Future of Food seminar organised by trade body UK Hospitality, researchers reported that about 7% of UK adults — roughly 3.6 million people — are using injectable weight‑loss medications. Analysis by KAM Insight presented at the event indicated that a third of those users reported dining out less often and that a quarter reduced their alcohol intake while at pubs and restaurants.
The hospitality sector has been monitoring shifts in consumer behaviour as new medicines for chronic weight management become more widely prescribed. Industry figures have warned that sustained reductions in portions consumed and lower spend on food and drink could affect turnover for businesses that rely on eating and drinking‑out occasions.
Blumenthal has publicly discussed both the personal and professional implications of the trend. "I've put on so much weight, but it's starting to come off now," he told Restaurant, referring to his experience on Wegovy. He reiterated concerns about the broader impact last week in comments to The Daily Mirror, saying: "We have another problem looming, a big one, a really big one [from a rise in weight‑loss drug prescriptions]. They're good, but people just won't eat as much."
The move to alter portion sizes follows a period of industry debate about how restaurants and pubs should respond — from changing menu structures to offering tasting‑size portions or different service formats — as some customers' appetites shift. Operators in some countries have already experimented with smaller plates, shareable dishes and expanded tasting menus to provide choice for guests with varying intake levels.
Blumenthal's announcement adds a high‑profile example to that industry conversation, given his status as one of the United Kingdom's best‑known chefs. He did not provide a detailed timetable for the menu changes or say whether the adjustments would be temporary or permanent. His restaurants have previously been noted for theatrical presentations and unconventional pairings; the proposed reduction in portion size is framed as a practical response to changing customer behaviour rather than a change in culinary philosophy.
UK Hospitality said the Future of Food seminar aimed to help the industry understand how wider societal changes are affecting demand. It did not immediately respond to a request to comment on Blumenthal's plans.
As prescription rates for GLP‑1 and related drugs increase, restaurateurs and pubs will continue to face decisions about how to balance culinary identity, customer expectations and commercial viability. Blumenthal's decision to pilot smaller portions at The Fat Duck underscores how medical and lifestyle trends are shaping the business strategies of even the most celebrated dining establishments.